| EYPT Shares Outstanding History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the EYPT shares outstanding history going back to 2/10/2010:
Also see: EYPT Market Cap History EYPT YTD Return |
EYPT Shares Outstanding History — EyePoint Pharmaceuticals Share Count Over Time
As of 5/1/2026 EyePoint Pharmaceuticals has 83.84 million EYPT shares outstanding. Investors often track the EYPT shares outstanding history to compare shareholder return trends against the change in share count over time.
This page shows EYPT share count trends over time, with 69 historical shares outstanding datapoints presented, dating back to 2/10/2010.
| EYPT Shares Outstanding History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EYPT Historical Shares Outstanding: +26.51% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EYPT Stock Price Chart |
| About EyePoint Inc |
| EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. Co. is focused on the business of developing and commercializing ophthalmic products for the treatment of eye diseases. Co.'s pipeline leverages its Durasert technology (Durasert) for sustained intraocular drug delivery, including delivery of EYP-1901, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases. Its additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. We show 69 historical shares outstanding datapoints in our coverage of EYPT's shares outstanding history. Understanding the changing numbers of EYPT shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like EYPT versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching EYPT by allowing them to research EYPT shares outstanding history as well as any other stock in our coverage universe. |
| EYPT Current Stock Quote |
Quotes delayed 20 minutes  Free EYPT Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: Shares Outstanding Importance | |
|
Video: Shares Outstanding Importance
| EYPT Share Performance |
| Shares Outstanding Peers |
| EyePoint Pharmaceuticals (EYPT) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:
FATE Shares Outstanding History FBIO Shares Outstanding History FBLG Shares Outstanding History FBRX Shares Outstanding History FCRE Shares Outstanding History FCSC Shares Outstanding History FDMT Shares Outstanding History FEED Shares Outstanding History FEMY Shares Outstanding History FGEN Shares Outstanding History More Healthcare companies » |
EYPT Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
